Evidence map›Paper›PMID 12592388›Full record

ArticleOncogene2003

Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).

Yutaka Masuda, Ayano Nishida, Kouichi Hori, Takahiro Hirabayashi, Sachiko Kajimoto, Shigeo Nakajo, Takeshi Kondo, Masahiro Asaka, Kazuyasu Nakaya

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Targeting Cancer Metabolism and Current Anti-Cancer Drugs.Advances in experimental medicine and biology · 2021
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yutaka MasudaLaboratory of Biological Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo 142-8555, Japan.
Ayano Nishida
Kouichi Hori
Takahiro Hirabayashi
Sachiko Kajimoto
Shigeo Nakajo
Takeshi Kondo
Masahiro Asaka
Kazuyasu Nakaya
Showa University · JPShowa Pharmaceutical University · JPHokkaido University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

beta-Hydroxyisovalerylshikonin (beta-HIVS), which was isolated from the plant, Lithospermum radix, induces apoptosis in various lines of human tumor cells. To identify genes involved in beta-HIVS-induced apoptotic process, we performed cDNA array analysis and found that beta-HIVS suppresses the expression of the gene for a polo-like kinase 1 (PLK1) that is involved in control of the cell cycle. When U937 and HL60 cells were treated with 10(-6) M beta-HIVS for 0.5 h, both the amount of PLK1 itself and the kinase activity of this enzyme were decreased. By contrast, Bcr-Abl-positive K562 cells were resistant to the induction of apoptosis by beta-HIVS and this compound did not suppress the kinase activity of PLK1 in these cells. However, simultaneous treatment of K562 cells with both beta-HIVS and STI571, which selectively inhibits the protein tyrosine kinase (PTK) activity of Bcr-Abl, strongly induced apoptosis. Moreover, beta-HIVS increased the inhibitory effect of STI571 on PTK activity. Treatment of K562 cells with antisense oligodeoxynucleotides (ODNs) specific for PLK1 sensitized these cells to the beta-HIVS-induced fragmentation of DNA. These results suggest that suppression of the activity of PLK1 via inhibition of tyrosine kinase activity by beta-HIVS might play a critical role in the induction of apoptosis.

Indexed as

Protein Kinase InhibitorsAntineoplastic Agents, PhytogenicApoptosisBenzamidesCell Cycle ProteinsCell LineCysteine Proteinase InhibitorsDNA, ComplementaryEnzyme InhibitorsFusion Proteins, bcr-ablGene Expression ProfilingGene Expression Regulation, LeukemicGenisteinHL-60 CellsHumansImatinib MesylateAntineoplastic Agents, PhytogenicBenzamidesbeta-hydroxyisovalerylshikoninCell Cycle ProteinsCysteine Proteinase InhibitorsDNA, ComplementaryEnzyme InhibitorsFusion Proteins, bcr-ablGenisteinImatinib MesylateNaphthoquinonesNeoplasm ProteinsOligodeoxyribonucleotides, AntisensePiperazinesPolo-Like Kinase 1Protein Kinase InhibitorsProtein KinasesProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Pyrimidines

Identifiers

PMID12592388
OpenAlexW2074056525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.